Compare Novo Nordisk A/S (NVO) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs VICI Properties Inc — how do they compare? Novo Nordisk A/S trades at $49.39 (market cap $220.53B), while VICI Properties Inc trades at $26.75 (market cap $29.55B). The key difference: Novo Nordisk A/S is far larger — about 7.5× VICI Properties Inc's market cap, and VICI Properties Inc pays the higher dividend (6.71%). Which is the better fit depends on your goals.
| NVO | VICI | |
|---|---|---|
Market Cap | $220.53B | $29.55B |
Sector | Health | Real Estate |
52-Week High | $71.70 | $33.93 |
52-Week Low | $35.29 | $25.94 |
Enterprise Value | $239.49B | $46.77B |
Dividend Yield | 3.63% | 6.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
VICI Properties trades at $26.83, down slightly (-0.15%) on the day. The stock shows strong fundamentals with a P/E of 9.19, net income margin of 76.83%, and consistent earnings beats in recent quarters. Technical indicators are mixed with an overall bullish signal but bearish moving averages. Recent news highlights institutional activity with CalPERS reducing its stake while Aviance Capital Partners initiated a new position.
VICI offers a compelling investment case with attractive valuation metrics, robust profitability, and a 6.62% dividend yield. However, risks include tenant concentration with Caesars/MGM accounting for 70% of rent and potential lease uncertainties from recent buyout discussions. Analyst consensus remains strongly bullish with a $29.00 price target suggesting 8% upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
